

1 **Quickly and simply detection for coronaviruses**
2 **including SARS-CoV-2 on the mobile Real-Time PCR**
3 **without treating RNA in advance**

4 Masaaki Muraoka^{1,2*}, Yukiko Tanoi¹, Tetsutaro Tada¹, Mikio Mizukoshi²,
5 Osamu Kawaguchi¹

6
7
8
9 ¹Business Innovation Center, Nippon Sheet Glass Co. Ltd., 5-8-1, Nishi-Hashimoto, Midori-
10 ku, Sagamihara-shi, Kanagawa, Japan

11
12 ²Certified Non-Profit Organization Biomedical Science Association, 2-20-8, Kamiosaki,
13 Shinagawa-ku, Tokyo, Japan

14
15 *Correspondence: masaaki.muraoka@nsg.com

16
17 Running Title; Real-time direct RT-PCR for SARS-CoV-2

18
19 Keyword; SARS-CoV-2, coronavirus, real-time RT-PCR, direct RT-PCR, quickly, rapidly,
20 simply, easily, mobile, RNA virus

21
22
23
24
25 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26 **ABSTRACT**

27 SARS-CoV-2 was reported to the WHO as an outbreak in Wuhan City, China on end of 2019,
28 afterwards pandemic on the worldwide in 2020. The SARS-CoV-2 virus is less deadly, but far
29 more transmissible. Therefore, it needs to detect and monitor quickly and simply on site to
30 prevent SARS-CoV-2.

31 If detecting coronaviruses including SARS-CoV-2, the real-time RT-PCR method is sensitive
32 and specific for the unique target, however, it must take long time and labour that RNA is
33 treated in advance, transcribed and amplified. Therefore, referenced previously report, in this
34 study, we modified various methods to prove hypotheses the followed.

35 Firstly, we hypothesized that real-time RT-PCR could be finished in very short time by the
36 mobile real-time PCR device and one-step RT-PCR reagent. Secondly, we hypothesized that it
37 was possible to perform RT-PCR utilizing the reagent as the above without RNA treatment in
38 advance so called “direct”.

39 Firstly, it was able to detect the positive control RNA of SARS-CoV-2 for less than 13.5
40 minutes by primer-probe referring to the CDC. Moreover, each detection value varied in
41 accordance with each concentration (This correlation coefficient $R^2 > 0.95$). Secondary, it was
42 possible to detect human coronavirus 229E with direct RT-PCR. Furthermore, each detection
43 value varied in accordance with each titer ($TCID_{50}$ / mL) of human coronavirus 229E (This
44 correlation coefficient $R^2 > 0.95$).

45 Considering the above, causing by utilizing the mobile real-time PCR device and the one-step
46 real-time PCR reagent simultaneously following as: 1) It was possible to detect SARS-CoV-2
47 in very short time as compared to conventional method; 2) It was possible to detect human
48 coronavirus quickly and simply with “direct”. For these reasons, we hypothesized that it is
49 possible to detect SARS-CoV-2 quickly and simply by utilizing methods the above without
50 treating RNA in advance. This hypothesis is our next try.

51

52 **STRENGTHS AND LIMITATIONS OF THIS STUDY**

53 * This study developed it possible to detect the positive control RNA of SARS-CoV-2 more
54 quickly than previously, however couldn't try to detect the genetic RNA.

55 * This study proved clearly that the human coronavirus instead of SARS-CoV-2 could be
56 detected simply without treating RNA in advance by the same method above.

57 * This study couldn't try to utilize the human specimens because of our institution limited.

58 * This study could utilize the device and the reagents commercial and not especial.

59

60 **INTRODUCTION**

61 Severe acute respiratory syndrome–coronavirus 2 (SARS-CoV-2) is a cause of coronavirus
62 disease 2019 (COVID-19) outbreak, of which the World Health Organization (WHO) declared
63 pandemic on March 11, 2020 [1]. COVID-19 was firstly reported to the WHO as an outbreak
64 in Wuhan City, Hubei Province, China on December 31, 2019, afterwards has rapidly spreading
65 [2]. SARS-CoV-2 included, human infectious coronaviruses have been known seven types.
66 Four of the seven types (HCoV-229E, HCoV-HKU1, HCoV-OC43, and HCoV-NL63) are
67 included among the known causes of common cold. Whereas, other three human coronaviruses
68 (the Middle East respiratory syndrome coronavirus [MERS-CoV], SARS-CoV, SARS-CoV-2)
69 are highly pathogenic and can cause severe diseases presented as acute respiratory distress
70 syndrome (ARDS) characterized by dysfunctional immune responses and severe pulmonary
71 injury [3, 4]. The SARS-CoV-2 virus is genetically closely related to SARS-CoV, but which is
72 less deadly and far more transmissible than MERS-CoV or SARS-CoV [5]. Therefore, it has
73 been needed with rapidity and on site to detect and monitor.

74 The conventional method of confirmation for SARS-CoV-2 is based on detection of sequences
75 unique in the virus RNA by nucleic acid amplification tests (NAAT) such as real-time reverse-

76 transcription polymerase chain reaction (RT-PCR). The viral genes targeted so far include the
77 nucleocapsid (N), envelop (E), RNA-dependent RNA polymerase (RdRP), spike (S), and open
78 reading frame 1 a/b (Orf1a/b), each of which primer and probe is various sequences [6, 7, 8, 9,
79 10, 11]. We recognize that the performance characteristics of PCR methods can vary with
80 reagents, PCR programs, and devices. Therefore, if devices or reagents changed, with simpler
81 and faster, it might be possible to detect.

82 Further, in quantitative RT-PCR, RNA extraction is required, followed by transcription,
83 amplification and detection. Current RT-PCR typically require more than 60 minutes for RNA
84 extraction, concentration and purification, and a further 90 minutes for transcription and
85 amplification [12]. It is difficult to handle RNA not to be damaged and lost, possible to infect
86 secondary and needed long time to detect. This might be due to the delay of the initial
87 introduction of RT-PCR detection for SARS-CoV-2 in various places.

88 As already reported rapid detection of SARS-CoV-2 with using mobile real-time PCR device
89 PCR1100 [10], we suggest “simpler and faster” method of RT-PCR in this paper as follows.

90

91 **MATERIALS AND METHODS**

92 **Primer and Probe**

93 Based on previously reported protocols of NIID [6, 7] and CDC [8, 9], and detection of
94 HCoV-229E [13], PCR primers and probes for real-time RT-PCR detection were selected to
95 target each N gene, and synthesised (Fasmac Co. Ltd., Japan) (Table 1).

96

97 **Sample**

98 Positive control RNA for SARS-CoV-2 against NIID version was kindly provided from
99 NIID (for N primer probe Ver.2 and N2 primer probe Ver.2 / Ver.3), and against CDC version

100 were synthesised (Fasmac Co. Ltd., Japan) based on each primer sequence and information
101 of GenBank: MN997409.1 (Table 2).

102 Each positive control RNA was applied 10-fold serial dilution with 10mM Tris-HCl (pH8.0
103 adjusted from 1M [Nippon Gene Co. Ltd., Japan] with water [UltraPure™ DNase / RNase-
104 Free Distilled Water, Thermo Fisher Scientific Inc., USA]) included 10µg / mL carrier RNA
105 (Ribonucleic acid from baker's yeast, Merck KGaA, Germany). Further, each concentration
106 of positive control RNA was assessed relatively with detection value of PCR1100.

107 The above, exposure to HCoV-229E is low-risk for healthy adults. The HCoV-229E virus
108 is easily accessible for the biosafety level 2 (BSL2) laboratory. Therefore, HCoV-229E may
109 be a good initial model for the evaluation against other coronaviruses, such as SARS-COV-
110 2, the coronavirus that causes COVID-19 [14]. There we substituted HCoV-229E for SARS-
111 2-CoV in direct RT-PCR. Human coronavirus 229E (HCoV-229E, VR-740™) was bought
112 by certified non-profit organization biomedical science association in Japan (BMSA) from
113 American Type Culture Collection (ATCC®, USA), afterwards, in cooperation of BMSA, it
114 was able to be used. Because to proliferate HCoV-229E, it was infected with MRC-5 cells
115 (CCL-171™, ATCC®), and cultured with EMEM medium (30-2003™, ATCC®) included
116 2% FBS (30-2020™, ATCC®) for 5~8 days in 5% CO₂ at 35 °C. When virus titer was grown
117 up 8.9 x 10⁶ Median tissue culture infectious dose (TCID₅₀ / mL), only that supernatant
118 without MRC-5 cells was stored at -80 °C before the assay. The supernatant included HCoV-
119 229E was thawed in the assay, not treated in advance and used with crude as it was. To assess
120 detection value of PCR1100 relative with titer of virus, the crude sample was applied 10-fold
121 serial dilution with 10mM Tris-HCl (pH8.0, the above).

122

123 **Real-time RT-PCR**

124 RT and PCR were carrying out in the one-step with using mobile real-time PCR device
125 PCR1100 for all tests of this study. Briefly describe the composition of RT-PCR reagent, 1 μ L
126 of a sample (the crude or positive control RNA) was amplified in a 17 μ L reaction solution
127 containing 1x Reaction Buffer, 0.25 μ L of RT Enzyme Mix, 1.0 μ L of DNA Polymerase
128 (THUNDERBIRD® Probe One-step qRT-PCR Kit, TOYOBO Co. Ltd., Japan), each final
129 concentration of primer and probe for target detection (Table 2). With preliminary tested, each
130 composition optimized (data not shown).

131 The RT-PCR conditions applied in this study were programmed as follows: RT incubation
132 and enzyme activation were serially performed at 50 °C for 150 seconds, at 95 °C for 15
133 seconds respectively. Afterwards, for SARS-CoV-2 against NIID version: thermal cycling was
134 then performed at 95 °C for 3.5 seconds (denaturation), and at 60 °C for 16 seconds (annealing
135 and amplification) for fifty cycles. For SARS-CoV-2 against CDC version: thermal cycling
136 was then performed at 95 °C for 3.5 seconds (denaturation), and at 60 °C for 7 seconds
137 (annealing and amplification) for fifty cycles. For HCoV-229E: thermal cycling was then
138 performed at 95 °C for 3.5 seconds (denaturation), and at 60 °C for 8 seconds (annealing and
139 amplification) for fifty cycles. With preliminary tested, each condition was optimized (data
140 not shown).

141 Incidentally, the procedure of PCR1100 was according to previously reported [15].

142

143 **RESULTS**

144 **Detection of SARS-CoV-2 in positive control RNA**

145 In NIID version, both No.1 and No.2 could be simultaneously detected with multichannel
146 (Fig 1). As the result previously reported [7], No.2 was detected more sensitive than No.1,
147 possible to determine 10 copies too. Each Ct value (detected on the PCR1100) was depended
148 on the rate of dilution (No.1: $R^2 = 0.9982$, No.2: $R^2 = 0.9969$). When simultaneously detecting

149 with two kinds of primer / probe sets, accuracy of results could be provided with higher
150 reliability. It took only about 20 minutes per detection on the PCR1100 with using one step
151 RT-PCR reagent (THUNDERBIRD® Probe One-step qRT-PCR Kit). So, it could be to detect
152 10 copies of positive control RNA only in 20 minutes.

153 In CDC version, also, CDC No.1 and CDC No.2 could be detected with multichannel (Fig
154 2). Both No.1 and No.2 were detected in same sensibility, and possible to detect 10 copies
155 too. Furthermore, each Ct value (detected on the PCR1100) was depended on the rate of
156 dilution (No.1: $R^2 = 0.9996$, No.2: $R^2 = 0.9983$). As the same of NIID version, when
157 simultaneously detecting with two kinds of primer / probe sets, accuracy of results could be
158 provided with higher reliability. Furthermore, it took only about 13.5 minutes per detection
159 on the PCR1100 with using the same one step RT-PCR reagent, that was even faster
160 compared with NIID version. It could detect with at least 10 copies of positive control RNA,
161 besides it took only in 13.5 minutes.

162

163 **Detection of HCoV-229E in crude state**

164 Crude sample of HCoV-229E was applied 10-fold serial dilution, afterwards without
165 treatment in advance and with one step RT-PCR reagent (THUNDERBIRD® Probe One-step
166 qRT-PCR Kit) was tested in the RT-PCR on the mobile real-time PCR device PCR1100. As
167 the result, without treatment for extraction, concentration and purification of RNA, it was
168 possible to detect HCoV-229E at least 8.9×10^2 TCID₅₀ / mL (Fig 3). Furthermore, each Ct
169 value (detected on the PCR1100) was depended on the rate of dilution, that is, virus titer (R^2
170 = 0.9949). Ct value might be relatively indicated to virus titer.

171 Also, it took only about 13 minutes per detection on the PCR1100 with using one step RT-
172 PCR reagent the same above of SARS-CoV-2. On another real-time PCR device using normal
173 two steps RT-PCR, it needed more than 90 minutes.

174 Therefore, it would be able to omit more than 135 minutes (60 minutes for RNA treatment,
175 75 minutes for RT-PCR) in total in detection of RNA virus compared with other current
176 methods.

177

178 **DISCUSSION**

179 Previously reported [10, 15, 16], with using the mobile real-time PCR device PCR1100, it
180 could be to detect unique strain rapidly, and sensibility and specificity are equivalent to other
181 devices. However, it would take 15 minutes at least to conclude RT-PCR for detection of unique
182 RNA in any case. Furthermore, it was necessary for RNA in advance to adjust with extraction,
183 concentration and purification.

184 First, this study addressed it to optimize each composition and PCR program according to
185 previously reported [7, 10], a part of which modified to quickly carry out RT-PCR for detection
186 of SARS-CoV-2 with using the mobile real-time PCR device PCR1100. With especially the
187 unit of reverse transcriptase enzyme decreased and the time of reverse transcription shorted,
188 sensibility of detection was improved (data not shown). Furthermore, as one step RT-PCR
189 reagent, THUNDERBIRD Probe One-step qRT-PCR Kit (TOYOBO) was used, of which was
190 possible and efficiently to carry out RT and probe' real-time PCR simultaneously. This time,
191 NIID and CDC version were selected for detection of SARS-CoV-2, both of which were unique
192 for N-gene of SARS-CoV-2 and used in general [7, 8, 9]. As a result, in the NIID version No.2,
193 CDC version No.1 and No.2, it was possible quantitatively to detect 10 copies or more of
194 positive control RNA with using mobile real-time PCR device PCR1100. However, in the NIID,
195 No.1 was able to detect only 100 copies or more, so No.2 was more sensitive than No.1 by 10
196 times. These results were about equal to previously reported [7, 10], that is, it might mean this
197 method to be right adequate to detect positive control RNA for SARS-CoV-2. Furthermore, in
198 both of CDC version by multichannel method, RT-PCR run could be finished in less than 14

199 minutes. That is, after RNA finished of extraction from each sample, this device would be
200 quickly able to discriminate presence of target. This faster RT-PCR might be caused by
201 combination of PCR1100 with RT-PCR reagent, of which was possible and efficiently to carry
202 out RT and PCR simultaneously. However, regretfully, in our situation unable to deal with
203 SARS-CoV-2, this method couldn't be demonstrated possible or not for genome RNA as
204 reported previously [7, 10]. Furthermore, primer / probe sets unique for gene of SARS-CoV-2
205 has been variously developed till now, so we would like to investigate about those sets if RT-
206 PCR is able to be faster to more in the PCR1100.

207 Second, we tried it to modify total system to detect SARS-CoV-2 easier. When treatment in
208 advance for RNA (mainly extraction, concentration and purification) it was required more than
209 60 minutes [12, 13, 17]. Therefore, in this study, we tried it to carry out RT-PCR without
210 treatment of RNA in advance, so that, direct RT-PCR. We tested for direct RT-PCR, in that
211 was used THUNDERBIRD® Probe One-step qRT-PCR Kit as one step RT-PCR reagent. With
212 above, this reagent was possible and efficiently to carry out RT and probe' real-time PCR
213 simultaneously, furthermore as reason, described possible to NAAT from crude samples [18].
214 Additionally, because of our situation unable to deal with SARS-CoV-2, therefore we
215 substituted HCoV-229E, low-risk for healthy, for SARS-2-CoV in direct RT-PCR this time. As
216 a result, surprisingly, without treatment for extraction, concentration and purification of RNA,
217 it was possible to detect HCoV-229E at least 8.9×10^2 TCID₅₀ / mL. Furthermore, Ct value
218 could be relatively to virus titer. This time, Lower Limit of Detection (LoD) couldn't show
219 accurately because failed to measure less than 8.9×10^2 TCID₅₀ / mL. However, as approximate
220 curve shown ($y = -4.004x + 46.61$), the LoD is supposed to less than 1 TCID₅₀ / mL. Also, it
221 took only about 13 minutes per detection on the PCR1100 with using one step RT-PCR reagent
222 the same above of SARS-CoV-2. Therefore, it would be able to omit more than 135 minutes
223 (60 minutes for RNA treatment, furthermore, 75 minutes for RT-PCR) in total in detection of

224 SARS-CoV-2 compared with other current methods. Already some reported direct RT-PCR for
225 SARS-CoV-2, it was necessary for especial reagent and additional treatment duration to direct
226 RT-PCR [12, 19, 20, 21, 22]. So, we could suggest novel method in this paper, in which used
227 PCR1100 device and commercial one step RT-PCR reagent only. However, our method must
228 be assessed in real SARS-CoV-2, further validated using clinical specimens, which contained
229 nasopharyngeal swabs and sputum. Furthermore, real-time RT-PCR reliable in saliva reported
230 [23, 24], its specimen must be assessed too. On the other hand, if low virus in air could be
231 collected, it might be able to detect quickly and easily on site by our novel method, and the
232 result be following prevent from droplet infection.

233 Although the other four community-acquired HCoVs (229E, OC43, HKU1, NL63) are a
234 common cause of common cold only, they are thought to cause pandemics and major outbreaks
235 of probably more severe respiratory diseases when they initially crossed species' barriers to
236 infect humans decades and centuries ago [3, 25]. That is, it would be possible new coronaviruses
237 to transfer again, therefore we are exposed to dangerous forever. On that time, the mobile real-
238 time PCR could be it save time compared to earlier detection methods. Furthermore, we think
239 that methods suggested in this paper should be suitable for various strains and it to be useful.

240

241 **STUDY DESIGN**

242 When each sample was assessed in the real-time RT-PCR, a ten-fold dilution series of each
243 was indicated with high relativity to Ct value on the mobile real-time PCR device PCR1100
244 ($R^2 = 0.99$).

245

246 **ACKNOWLEDGEMENTS**

247 We thank Dr. Kazuya Shirato and Dr. Tsutomu Kageyama at the National Institute of
248 Infections Disease in Japan (NIID) for positive control or technical comments, and Takashi

249 Fukuzawa in an ex-employee at Nippon Sheet Glass Co. Ltd. for technical comments or
250 experimental help.

251

252 **AUTHOR CONTRIBUTIONS**

253 M. Muraoka conceived, designed experiments, performed experiments, analysed the data and
254 wrote the manuscript. Y. Tanoi performed experiments and analysed the data. T. Tada wrote
255 the manuscript. M. Mizukoshi conceived and provided specimens. O. Kawaguchi conceived
256 and designed experiments. All authors also participated in the editorial process and approved
257 the manuscript.

258

259 **ETHICAL STATEMENT**

260 This study did not contain any studies involving human participants and animals performed
261 by any of the authors.

262

263 **COMPETING INTERESTS**

264 The authors declare that no competing interests exist. While M. Muraoka, T. Tanoi, T. Tada,
265 and O. Kawaguchi were employed at Nippon Sheet Glass at the time of this study, in where all
266 did not create a competing interest. Further, Nippon Sheet Glass had no involvement in this
267 study.

268

269 **REFERENCES**

270 [1] World Health Organization (WHO). WHO characterizes COVID-19 as a pandemic.
271 Rolling updates on coronavirus disease (COVID-19). Updated 11 March 2020.

- 272 Available from: <https://www.who.int/emergencies/diseases/novel-coronavirus->
273 [2019/events-as-they-happen](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen)
- 274 [2] World Health Organization (WHO). 2019 Novel Coronavirus: Overview of the state of the
275 art and outline of key knowledge gaps/slides. Published 12 February 2020.
276 Available from: [https://www.who.int/publications/m/item/2019-novel-coronavirus-](https://www.who.int/publications/m/item/2019-novel-coronavirus-overview-of-the-state-of-the-art-and-outline-of-key-knowledge-gaps-slides)
277 [overview-of-the-state-of-the-art-and-outline-of-key-knowledge-gaps-slides](https://www.who.int/publications/m/item/2019-novel-coronavirus-overview-of-the-state-of-the-art-and-outline-of-key-knowledge-gaps-slides)
- 278 [3] Sin-Yee Fung, et al. A tug-of-war between severe acute respiratory syndrome coronavirus
279 2 and host antiviral defence: lessons from other pathogenic viruses. *Emerg Microbes*
280 *Infect.*, 2020; 9(1): 558-570.
281 [doi: 10.1080/22221751.2020.1736644](https://doi.org/10.1080/22221751.2020.1736644)
- 282 [4] Puja Mehta, et al. COVID-19: consider cytokine storm syndromes and immunosuppression.
283 *Lancet*, 2020; 395(10229): 1033–1034.
284 [doi: 10.1016/S0140-6736\(20\)30628-0](https://doi.org/10.1016/S0140-6736(20)30628-0)
- 285 [5] Eskild Petersen, et al. Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics.
286 *Lancet Infect. Dis.*, 2020; 20(9): E238-E244.
287 [doi: 10.1016/S1473-3099\(20\)30484-9](https://doi.org/10.1016/S1473-3099(20)30484-9)
- 288 [6] Victor M Corman, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time
289 RT-PCR. *Euro Surveill.*, 2020; 25(3): pii=2000045.
290 [doi: 10.2807/1560-7917.ES.2020.25.3.2000045](https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045)
- 291 [7] Kazuya Shirato, et al. Development of Genetic Diagnostic Methods for nCoV-2019 in
292 Japan. *Jpn. J. Infect. Dis.*, 2020; 73(4).
293 [doi: 10.7883/yoken.JJID.2020.061](https://doi.org/10.7883/yoken.JJID.2020.061)
- 294 [8] Centers for Disease Control and Prevention. 2019-Novel Coronavirus (2019-nCoV) Real-
295 time rRT-PCR Panel Primers and Probes. Updated 6 June 2020.

- 296 Available from: <https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-panel-primer->
297 [probes.html](https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-panel-primer-probes.html)
- 298 [9] Yu Jin Jung, et al. Comparative analysis of primer-probe sets for the laboratory
299 confirmation of SARS-CoV-2. bioRxiv [Preprint], Posted 27 February 2020.
300 [doi: 10.1101/2020.02.25.964775](https://doi.org/10.1101/2020.02.25.964775)
- 301 [10] Kazuya Shirato, et al. An ultra-rapid real-time RT-PCR method using the PCR1100 to
302 detect Severe Acute Respiratory Syndrome Coronavirus-2. Jpn. J. Infect. Dis. [Advance
303 Publication], Released 30 June 2020.
304 [doi: 10.7883/yoken.JJID.2020.324](https://doi.org/10.7883/yoken.JJID.2020.324)
- 305 [11] World Health Organization (WHO). Laboratory testing for 2019 novel coronavirus (2019-
306 nCoV) in suspected human cases. Published 19 March 2020.
307 Available from: [https://www.who.int/publications/i/item/laboratory-testing-for-2019-](https://www.who.int/publications/i/item/laboratory-testing-for-2019-novel-coronavirus-in-suspected-human-cases-20200117)
308 [novel-coronavirus-in-suspected-human-cases-20200117](https://www.who.int/publications/i/item/laboratory-testing-for-2019-novel-coronavirus-in-suspected-human-cases-20200117)
- 309 [12] Soon Keong Wee, et al. Rapid Direct Nucleic Acid Amplification Test without RNA
310 Extraction for SARS-CoV-2 Using a Portable PCR Thermocycler. Genes (Basel), 2020;
311 11(6): 664.
312 [doi: 10.3390/genes11060664](https://doi.org/10.3390/genes11060664)
- 313 [13] Leontine J R van Elden, et al. Frequent Detection of Human Coronaviruses in Clinical
314 Specimens from Patients with Respiratory Tract Infection by Use of a Novel Real-Time
315 Reverse-Transcriptase Polymerase Chain Reaction. J. Infect. Dis., 2004; 189(4): 652–657.
316 [doi: 10.1086/381207](https://doi.org/10.1086/381207)
- 317 [14] Keykavous Parang, et al. Comparative Antiviral Activity of Remdesivir and Anti-HIV
318 Nucleoside Analogs Against Human Coronavirus 229E (HCoV-229E). Molecules, 2020;
319 25(10): 2343.
320 [doi: 10.3390/molecules25102343](https://doi.org/10.3390/molecules25102343)

- 321 [15] Kazuya Shirato, et al. Ultra-Rapid Real-Time RT-PCR Method for Detecting Middle East
322 Respiratory Syndrome Coronavirus Using a Mobile PCR Device, PCR1100. Jpn. J. Infect.
323 Dis., 2020; 73(3): 181-186.
324 [doi: 10.7883/yoken.JJID.2019.400](https://doi.org/10.7883/yoken.JJID.2019.400)
- 325 [16] Kazuya Shirato, et al. An ultra-rapid real-time RT-PCR method for detecting human
326 orthopneumovirus using PCR1100. Jpn. J. Infect. Dis. [Advance Publication], Released 29
327 May 2020.
328 [doi: 10.7883/yoken.JJID.2020.182](https://doi.org/10.7883/yoken.JJID.2020.182)
- 329 [17] Centers for Disease Control and Prevention. CDC Influenza SARS-CoV-2 (Flu SC2)
330 Multiplex Assay. Updated 9 July 2020.
331 Available from: <https://www.fda.gov/media/139743/download>
- 332 [18] TOYOBO Co. Ltd., Japan. TOYOBO Life Science Raw Material Catalog. Published 1
333 March 2019: p1.
334 Available from: <http://www.bio-toyobo.cn/pdf/RawMaterialCatalog.pdf>
- 335 [19] Emily A Bruce, et al. DIRECT RT-qPCR DETECTION OF SARS-CoV-2 RNA FROM
336 PATIENT NASOPHARYNGEAL SWABS WITHOUT AN RNA EXTRACTION STEP.
337 bioRxiv [Preprint], Posted 6 April 2020.
338 [doi: 10.1101/2020.03.20.001008](https://doi.org/10.1101/2020.03.20.001008)
- 339 [20] Licia Bordi, et al. Rapid and sensitive detection of SARS-CoV-2 RNA using the
340 Simplexa™ COVID-19 direct assay. J. Clin. Virol., 2020; 128: 104416.
341 [doi: 10.1016/j.jcv.2020.104416](https://doi.org/10.1016/j.jcv.2020.104416)
- 342 [21] Natacha Merindol, et al. SARS-CoV-2 detection by direct rRT-PCR without RNA
343 extraction. J. Clin. Virol., 2020; 128: 104423.
344 [doi: 10.1016/j.jcv.2020.104423](https://doi.org/10.1016/j.jcv.2020.104423)

- 345 [22] Mohammad Rubayet Hasan, et al. Detection of SARS-CoV-2 RNA by direct RT-qPCR
346 on nasopharyngeal specimens without extraction of viral RNA. PLoS One, 2020; 15(7):
347 e0236564.
348 [doi: 10.1371/journal.pone.0236564](https://doi.org/10.1371/journal.pone.0236564)
- 349 [23] Kelvin Kai-Wang To, et al. Consistent detection of 2019 novel coronavirus in saliva. Clin.
350 Infect. Dis., 2020; 71(15): 841-843.
351 [doi: 10.1093/cid/ciaa149](https://doi.org/10.1093/cid/ciaa149)
- 352 [24] Lorenzo Azzi, et al. Saliva is a reliable tool to detect SARS-CoV-2. J. Infect., 2020; 81(1):
353 e45-e50.
354 [doi: 10.1016/j.jinf.2020.04.005](https://doi.org/10.1016/j.jinf.2020.04.005)
- 355 [25] Victor M. Corman, et al. Chapter Eight - Hosts and Sources of Endemic Human
356 Coronaviruses. Adv. Virus Res., 2018; 100: 163-188.
357 [doi: 10.1016/bs.aivir.2018.01.001](https://doi.org/10.1016/bs.aivir.2018.01.001)
358
359
360
361
362
363
364
365
366
367
368
369
370
371

372 **Table 1. Selected primers and probes for the real-time RT-PCR of SARS-CoV-2**
373 **NIID and CDC, and HCoV-229E**

target	primer/probe	Sequence	final conc.
N_Sarbeco (NIID No.1)	N_Sarbeco_F	5'-CAC ATT GGC ACC CGC AAT C-3'	0.40μM
	N_Sarbeco_R	5'-GAG GAA CGA GAA GAG GCT TG-3'	0.60μM
	N_Sarbeco_P	5'-FAM-ACT TCC TCA AGG AAC AAC ATT GCC A-BHQ-3'	0.20μM
NIID_2019- nCOV_N2 (NIID No.2)	NIID_2019- nCOV_N_F2	5'-AAA TTT TGG GGA CCA GGA AC-3'	0.40μM
	NIID_2019- nCOV_N_R2 ver3	5'-TGG CAC CTG TGT AGG TCA AC-3'	0.60μM
	NIID_2019- nCOV_N_P2	5'-Cy5-ATG TCG CGC ATT GGC ATG GA-BHQ-3'	0.20μM
2019- nCoV_N1 (CDC No.1)	2019-nCoV_N1-F	5'-GAC CCC AAA ATC AGC GAA AT-3'	0.20μM
	2019-nCoV_N1-R	5'-TCT GGT TAC TGC CAG TTG AAT CTG-3'	0.20μM
	2019-nCoV_N1-P	5'-FAM-ACC CCG CAT TAC GTT TGG TGG ACC-BHQ-3'	0.20μM
2019- nCoV_N2 (CDC No.2)	2019-nCoV_N2-F	5'-TTA CAA ACA TTG GCC GCA AA-3'	0.40μM
	2019-nCoV_N2-R	5'-GCG CGA CAT TCC GAA GAA-3'	0.40μM
	2019-nCoV_N2-P	5'-HEX-ACA ATT TGC CCC CAG CGC TTC AG-BHQ-3'	0.20μM
HCoV- 229E_N	HCoV-229E_NF	5'-CAG TCA AAT GGG CTG ATG CA-3'	0.30μM
	HCoV-229E_NR	5'-AAA GGG CTA TAA AGA GAR* TAA GGT ATT CT-3'	0.30μM
	HCoV-229E_NP	5'-FAM-CY**C TGA CGA CCA CGT TGT GGT TCA-BHQ-3'	0.20μM

374 *R= A or G, **Y= C or T
375 Probe: N_Sarbeco_P was attached with 6-carboxyfluorescein (FAM) at the 5' end, probe:
376 NIID_2019-nCOV_N_P2 with cyan 5 (Cy5), probe: 2019-nCoV_N1-P with FAM, probe:
377 2019-nCoV_N1-P with HEX, and probe: HCoV-229E_NP with FAM. ALL probes were
378 attached with Black Hole Quencher (BHQ, Biosearch Technologies, Inc., USA) at the 3'
379 end. As above, NIID version or CDC version could be used with multichannel.

380

381

382

383 **Table 2. Sequences of positive RNA control for the real-time RT-PCR of SARS-**
384 **CoV-2 of CDC version.**

2019-nCoV_N1	ACA AAC UAA AAU GUC UGA UAA UGG ACC CCA AAA UCA GCG AAA UGC ACC CCG CAU UAC GUU UGG UGG ACC CUC AGA UUC AAC UGG CAG UAA CCA GAA UGG AGA ACG CAG UGG GGC GCG AUC
2019-nCoV_N2	CUA AUC AGA CAA GGA ACU GAU UAC AAA CAU UGG CCG CAA A UU GCA CAA UUU GCC CCC AGC GCU UCA GCG UUC UUC GGA AUG UCG CGC AUU GGC AUG GAA GUC ACA CCU UC

385

386

387


388

389

390

391

392



393

394 **Fig 1. Correlation of copies number and Ct value when detection of positive control**

395 **for NIID version on the PCR1100.**

396

397

398

399

400

401

402

403

404



405

406

407

408

409




412 **Fig 2. Correlation of copies number and Ct value when detection of positive control**
413 **for CDC version on the PCR1100. The top is CDC version No.1 (2019-**
414 **nCoV_N1), the bottom is No.2 (2019-nCoV_N2).**

415

416

417

418



419

420

Fig 3. Correlation of virus titer and Ct value when detection of HCoV-229E on the

421

PCR1100.